The NCL was founded in 2004 in collaboration with NCI, FDA and NIST to provide free preclinical characterization of cancer nanomedicines to support their clinical translation. NCL also serves as an R&D partner for non-oncology nanomaterials, reformulation, and a variety of other applications. We have a multi-disciplinary staff of 25 scientists with expertise in chemistry, pharmacology, toxicology, cancer biology, immunology, and formulation science. Since our founding, the NCL has characterized roughly 400 nanoparticles of all different types, collaborated with more than 100 universities and companies worldwide, and helped advance 10 products into/through clinical trials.
COVID-19 is an emerging, rapidly evolving situation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus